BIIB SEC Filings

Biogen Inc. reported total revenue of $2.74 billion for the three months ended June 30, 2026, a 3.4% increase from the prior year period. This growth was primarily driven by the inclusion of new specialized immunology products, SYFOVRE and EMPAVELI, acquired through the Apellis acquisition, and strong performance in rare disease products like SPINRAZA and SKYCLARYS. However, revenue from the Multiple Sclerosis portfolio, particularly TECFIDERA, saw a significant decline due to ongoing generic competition. Net income for the quarter was $97.5 million, a substantial decrease compared to $634.8 million in the same period last year, largely due to increased costs associated with the Apellis acquisition, including higher cost of sales, R&D expenses, and significant restructuring charges related to the integration. For the six months ended June 30, 2026, total revenue rose by 2.7% to $5.21 billion, while net income decreased to $417.0 million from $875.3 million in the prior year. The company's operational expenses saw a notable increase, driven by higher amortization from inventory step-ups, increased R&D spending on late-stage programs, and the expanded commercial operations of Apellis. Despite these cost pressures and the continued decline in the MS franchise, the company is focused on the growth of its rare disease and specialized immunology portfolios and strategic investments in its pipeline.

Biogen Inc. (BIIB) has filed a Form 8-K on July 29, 2026, to announce its financial results for the second quarter ended June 30, 2026. The primary purpose of this filing is to furnish a press release detailing the company's operational and financial performance during the period. Investors should refer to the furnished press release (Exhibit 99.1) for specific details on revenue, earnings, and other key financial metrics, as well as any forward-looking statements or guidance provided by the company. While the 8-K itself is brief, it signifies the official release of Biogen's quarterly performance data. It's crucial for investors to access and analyze the accompanying press release for a comprehensive understanding of the company's recent financial health, strategic updates, and outlook. The information provided in the press release will be instrumental in evaluating Biogen's current standing and future prospects within the biotechnology sector.

Biogen Inc. (BIIB) has filed a Form 8-K on July 1, 2026, to provide preliminary updates on its expected financial results for the second and third quarters of 2026. The primary driver of the disclosed impact is acquired in-process research and development (IPR&D), upfront, and milestone expenses related to collaborations and license agreements. These costs are significant and are expected to impact both GAAP and non-GAAP earnings per diluted share. For the second quarter of 2026, Biogen anticipates an IPR&D expense of approximately $164 million pre-tax, translating to an impact of roughly $0.95 per diluted share. Looking ahead to the third quarter of 2026, the company expects a broader range of IPR&D expenses, estimated between $290 million and $320 million, which could affect earnings per diluted share by approximately $1.75 to $1.95. Investors should note that these are preliminary estimates and are subject to change as financial closing procedures are completed.

Biogen Inc. (BIIB) filed an 8-K on June 10, 2026, reporting the final voting results from its 2026 Annual Meeting of Stockholders held on June 9, 2026. The meeting's primary outcomes included the election of ten directors to the Board and the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026. Additionally, stockholders provided an advisory vote on executive compensation. Investors can view the detailed voting outcomes for each director nominee, which indicate overwhelming support for most candidates, with a few exceptions receiving notably fewer 'for' votes but still comfortably elected. The ratification of the auditor and the advisory vote on executive compensation also received significant stockholder approval, suggesting general confidence in the company's governance and financial oversight for the upcoming fiscal year.

Biogen Inc. (BIIB) has filed an amendment to its previous 8-K filing dated May 14, 2026. The company is clarifying that the previously disclosed acquisition of Apellis Pharmaceuticals, Inc. did not constitute a "significant" acquisition under Regulation S-X. Consequently, Biogen will not be filing the financial statements of Apellis or the pro forma financial information related to the merger as initially anticipated. This amendment is primarily an administrative update to correct the reporting requirements associated with the Apellis acquisition. Investors should note that this filing does not alter the fundamental terms or completion of the acquisition itself, but rather clarifies the regulatory reporting obligations post-transaction. The original disclosures regarding the consummation of the merger remain unchanged.

Biogen Inc. (BIIB) has filed an 8-K on May 14, 2026, detailing the successful completion of its acquisition of Apellis Pharmaceuticals, Inc. The tender offer for Apellis shares concluded on May 13, 2026, with approximately 82.4% of shares tendered. Following the tender offer, Biogen completed the merger, making Apellis a wholly-owned subsidiary. The acquisition was financed through a combination of cash and $2 billion in term loan facilities secured on May 12, 2026. Key to the transaction are the Contingent Value Rights (CVRs) issued to Apellis shareholders, entitling them to potential future cash payments of up to $4.00 per CVR if specific net sales milestones for SYFOVRE® and related products are met between 2027 and 2031. Additionally, Biogen has entered into a new credit agreement, borrowing $2 billion to fund the acquisition and related expenses, which includes financial covenants such as a maximum consolidated leverage ratio of 3.75 to 1.0.

Biogen Inc. reported solid financial results for the first quarter of 2026, demonstrating revenue growth and improved profitability. Total revenue increased by 1.9% to $2,477.8 million, driven primarily by growth in revenue from anti-CD20 therapeutic programs and the Alzheimer's collaboration. Net income attributable to Biogen Inc. saw a significant increase of 33.1% to $319.5 million, leading to diluted earnings per share of $2.15, up from $1.64 in the prior year. This improvement was supported by a decrease in total costs and expenses, notably a significant reduction in acquired in-process research and development expenses. The company also maintained a strong liquidity position, with cash, cash equivalents, and marketable securities totaling $4.7 billion. Furthermore, Biogen announced a significant development with an agreement to acquire Apellis Pharmaceuticals for approximately $5.6 billion, expected to enhance its immunology and rare disease portfolio.

Biogen Inc. (BIIB) has filed an 8-K report on April 29, 2026, primarily to furnish its first-quarter 2026 earnings press release. This filing indicates that the company is providing an update on its financial performance for the period ending March 31, 2026. Investors should refer to the furnished press release (Exhibit 99.1) for the detailed financial results and operational highlights announced by the company on the same date. It is important to note that this information is furnished and not deemed "filed" for regulatory purposes, meaning it doesn't carry the same legal implications under Section 18 of the Exchange Act. The core information for investors will be contained within the press release itself, which would typically cover revenue, earnings per share (EPS), operating expenses, and potentially updates on key drug pipelines and commercial performance. Given this is an earnings announcement, the market will be scrutinizing these figures against expectations and prior periods to gauge the company's trajectory and future outlook. Investors should look for any commentary on strategic initiatives, regulatory updates, or significant business developments discussed in the press release.

Biogen Inc. has filed an 8-K report on April 6, 2026, to provide preliminary insights into its first quarter 2026 financial results. The company anticipates recognizing approximately $34 million in pre-tax acquired in-process research and development (R&D), upfront, and milestone expenses. This is expected to negatively impact both GAAP and non-GAAP earnings per diluted share by approximately $0.19 for the quarter. These expenses are typically associated with collaboration and licensing agreements, including upfront and milestone payments, and can also involve premiums on equity securities or asset acquisitions related to in-process R&D. Biogen notes that such expenses are inherently difficult to forecast due to the unpredictable nature of future transactions. Investors should consider this a preliminary disclosure, as final results are subject to financial statement closing procedures and may differ.

Biogen Inc. has announced a definitive agreement to acquire Apellis Pharmaceuticals, Inc. through a tender offer and subsequent merger. The proposed transaction involves an upfront cash payment of $41.00 per share of Apellis common stock, plus a contingent value right (CVR) entitling holders to potential future payments of up to $4.00 per share. The CVR payments are tied to specific net sales milestones for SYFOVRE® and related products in future years. This acquisition aims to bolster Biogen's portfolio, particularly in areas where Apellis has established a presence. The deal is structured as a tender offer by Biogen's subsidiary, Aspen Purchaser Sub, Inc., to acquire all outstanding shares of Apellis. This will be followed by a merger under Delaware law, allowing the transaction to be completed without a shareholder vote for Apellis, provided a minimum tender condition is met. The transaction is subject to customary closing conditions, including antitrust approvals. The agreement includes provisions for a termination fee under certain circumstances and has secured support from key Apellis stockholders. Investors should note that the offer has not yet commenced, and further details will be provided in subsequent filings. The transaction is not subject to a financing condition, and Biogen has committed to filing necessary antitrust notifications promptly. This move signifies a significant strategic step for Biogen to expand its therapeutic offerings and market reach.

Biogen Inc. (BIIB) has announced a key executive change via an 8-K filing dated March 11, 2026. Susan H. Alexander, the Company's Chief Legal Officer, will be departing her role effective at the end of May 2026. This transition marks the end of Ms. Alexander's tenure in a critical leadership position within the organization. The Company has confirmed that a search process is underway to recruit a successor for the Chief Legal Officer position. Investors should monitor the Company's communication for updates on the appointment of a new CLO, as this role is integral to legal and regulatory compliance, strategic decision-making, and risk management. The timing and profile of the incoming CLO could provide insights into Biogen's future strategic direction and governance.

Biogen Inc. (BIIB) announced a significant leadership transition in its latest 8-K filing. Caroline Dorsa, the current Chair of the Board, will not seek re-election at the upcoming 2026 Annual Meeting of Stockholders. The company has clarified that this decision is amicable and not driven by any disputes regarding Biogen's operations, policies, or practices. This change marks the end of Ms. Dorsa's tenure as Chair, a position she has held, and signals a shift in board leadership for the biotechnology firm. In conjunction with this change, the Board has elected Dr. Maria C. Friere to succeed Ms. Dorsa as the Chair of the Board, effective immediately following the Annual Meeting. Dr. Friere's appointment represents a continuation of leadership development within the Board, and investors will be keen to understand her vision and strategic priorities for Biogen. While the filing does not provide details on the specific reasons for Ms. Dorsa's departure beyond her decision not to seek re-election, the smooth transition to Dr. Friere suggests continued stability and a focused approach to governance.

Biogen Inc. (BIIB) has filed a Form 8-K on February 6, 2026, to report its financial results for the fourth quarter and full year ended December 31, 2025. The core of this filing is the accompanying press release (Exhibit 99.1), which details the company's operational performance and financial condition. Investors should review this press release for specific figures regarding revenue, profitability, and other key financial metrics for the period. While the 8-K itself is a formal notification of the results announcement, the substantive details are contained within the furnished press release. This report serves as an official communication channel for the market to access Biogen's latest financial performance indicators. Investors are advised to consult Exhibit 99.1 for a comprehensive understanding of Biogen's fourth-quarter and year-end 2025 financial outcomes and their potential implications.

Biogen Inc. (BIIB) reported its annual results for the fiscal year ending December 31, 2025. The company experienced a modest increase in total revenue, driven by strong performance in its Rare Disease segment, particularly from the launches of SKYCLARYS and QALSODY, and continued growth for ZURZUVAE. However, this was partially offset by a decline in Multiple Sclerosis (MS) revenue due to increased competition for TECFIDERA and TYSABRI, and a decrease in Biosimilars revenue. Strategic business development activities in 2025 included several key acquisitions and collaborations aimed at strengthening Biogen's pipeline, particularly in neurology and rare diseases. Notably, the company acquired Alcyone Therapeutics and entered into significant collaborations with Dayra, Vanqua Bio, City Therapeutics, and Stoke Therapeutics. These moves underscore Biogen's commitment to expanding its portfolio and addressing unmet medical needs in complex diseases.

Biogen Inc. has filed an 8-K report providing preliminary unaudited estimates for its fourth quarter of 2025 financial results. The company anticipates a significant charge of approximately $222 million on a pre-tax basis related to acquired in-process research and development, upfront, and milestone expenses. This is expected to reduce both GAAP and non-GAAP net income per diluted share by roughly $1.26. Investors should note that these are preliminary estimates and subject to change as financial closing procedures are completed. The company emphasizes the forward-looking nature of these statements and the inherent risks and uncertainties associated with such projections, urging investors to consult detailed risk factors in their SEC filings.

Biogen Inc. reported solid financial results for the third quarter and first nine months of 2025, demonstrating revenue growth driven by key product lines. Total revenue increased by 2.8% year-over-year to $2.53 billion for the quarter, with product revenue showing a 4.4% increase to $1.85 billion. This growth was primarily fueled by the Rare Disease segment, up 7.8%, and a 0.7% increase in Multiple Sclerosis (MS) revenue, with VUMERITY and TYSABRI showing particular strength, despite continued generic competition for TECFIDERA. The company also saw substantial growth in its Alzheimer's collaboration revenue, up 129.6% year-over-year, reflecting increased sales of LEQEMBI. Despite revenue growth, the company faced increased costs, notably in Cost of Sales, up 5.6% driven by a litigation charge and higher SKYCLARYS inventory step-up amortization. However, Research and Development (R&D) expenses decreased by 15.5%, partly due to cost-saving measures and R&D funding from Royalty Pharma, while Selling, General, and Administrative (SG&A) expenses saw a modest increase to support product launches. Diluted earnings per share (EPS) rose by 19.2% to $3.17, reflecting the revenue growth and improved R&D efficiency. Biogen's liquidity remains strong, with cash, cash equivalents, and marketable securities increasing to $4.0 billion.

Biogen Inc. (BIIB) has filed a Form 8-K on October 30, 2025, to report its financial results for the third quarter ended September 30, 2025. The core of this filing is the press release detailing the company's performance during the quarter, which is furnished as Exhibit 99.1. Investors should refer to this press release for specific details on revenue, profitability, and any significant operational updates that impacted the quarter's financial outcomes. While the 8-K itself is a procedural filing to announce these results, the accompanying press release contains the substantive financial and operational information. Investors are encouraged to review the press release for a comprehensive understanding of Biogen's third-quarter performance, including key financial metrics and management's commentary on the business outlook. This information is crucial for assessing the company's current financial health and future prospects.

Biogen Inc. (BIIB) has filed an 8-K report to disclose preliminary financial information for the third quarter of 2025. The company anticipates a pre-tax charge of approximately $2 million related to acquired in-process research and development, upfront, and milestone expenses. This is expected to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.01 for the quarter. This specific expense category was introduced in Q1 2025 and encompasses costs from collaboration and license agreements, including upfront and milestone payments, and in some cases, premiums on equity securities and asset acquisitions of acquired in-process R&D. Biogen notes that such expenses are difficult to forecast due to their inherent uncertainty in timing and magnitude. Investors should be aware that these are preliminary estimates and subject to change upon finalization of financial closing procedures.

Biogen Inc. reported total revenue of $2,645.5 million for the three months ended June 30, 2025, an increase of 7.3% compared to the same period in the prior year. This growth was primarily driven by a significant increase in Alzheimer's collaboration revenue (LEQEMBI) and contract manufacturing, royalty, and other revenue. However, product revenue experienced a slight decline of 1.1%, largely due to ongoing competition for its Multiple Sclerosis (MS) portfolio, particularly from generic versions of TECFIDERA and a TYSABRI biosimilar. Net income attributable to Biogen Inc. rose to $634.8 million, or $4.33 per diluted share, up from $583.6 million, or $4.00 per diluted share, in the prior year's quarter. This improvement was supported by the top-line growth and a substantial reduction in Research and Development (R&D) expenses, partially offset by higher cost of sales and selling, general, and administrative (SG&A) expenses. The company ended the period with a strong liquidity position, with cash and cash equivalents totaling $2.8 billion.

Biogen Inc. (BIIB) has filed an 8-K report on July 31, 2025, to announce its financial results for the second quarter ended June 30, 2025. The key details of these results are contained within a press release furnished as Exhibit 99.1 to the filing. Investors should refer to this press release for specific financial performance metrics, including revenue, profitability, and any significant operational updates impacting the company's financial condition. This filing is made under Item 2.02, which means the press release is furnished and not deemed 'filed' for certain regulatory purposes. While it provides crucial information for understanding Biogen's recent performance, it's important to note that this disclosure does not alter the company's legal obligations under the Securities Exchange Act of 1934 or the Securities Act of 1933. Investors should consult the press release directly for comprehensive insights into the second quarter's financial outcomes and any forward-looking statements the company may have made.

Biogen Inc. (BIIB) has issued a Current Report on Form 8-K disclosing anticipated financial results for the second quarter of 2025. The company expects to incur approximately $46 million in acquired in-process research and development, upfront, and milestone expenses on a pre-tax basis. This charge is estimated to reduce both GAAP and non-GAAP earnings per diluted share by approximately $0.26 for the quarter.

Biogen Inc. (BIIB) filed an 8-K on June 23, 2025, reporting the final voting results from its 2025 Annual Meeting of Stockholders held on June 17, 2025. The primary focus of this filing is the outcome of shareholder votes on key corporate governance matters, including the election of directors and the ratification of the independent auditor. The results indicate strong shareholder support for the company's proposed slate of eleven director nominees and the reappointment of PricewaterhouseCoopers LLP as its auditor for the upcoming fiscal year. Additionally, shareholders provided an advisory vote on executive compensation, the results of which are detailed in the filing.

Biogen Inc. (BIIB) announced the completion of a significant debt offering, successfully issuing and selling $1.75 billion in aggregate principal amount of senior unsecured notes on May 12, 2025. This offering consists of three tranches: $400 million of 5.050% Senior Notes due 2031, $650 million of 5.750% Senior Notes due 2035, and $700 million of 6.450% Senior Notes due 2055. The company intends to use the net proceeds from this issuance, along with existing cash, to fully retire its outstanding $1.75 billion of 4.050% Senior Notes due 2025. This strategic refinancing aims to extend Biogen's debt maturity profile and potentially optimize its interest expense.

Biogen Inc. reported total revenue of $2.43 billion for the first quarter of 2025, a 6.1% increase year-over-year, driven primarily by growth in rare disease products and higher contract manufacturing revenue. However, net income attributable to Biogen Inc. decreased significantly by 39.0% to $240.5 million, or $1.64 per diluted share, compared to $393.4 million, or $2.70 per diluted share, in the prior year's quarter. This decline was largely due to increased acquired in-process R&D, upfront and milestone expenses, primarily related to the acquisition of HI-Bio and collaboration with Stoke Therapeutics, as well as higher cost of sales. Despite the decrease in profitability, the company's cash position strengthened to $2.6 billion. Key product segments showed mixed performance. While revenue from multiple sclerosis (MS) products declined 11.4% due to increased competition, particularly from generics and biosimilars, rare disease revenue surged by 32.9%. This growth in rare diseases was bolstered by strong performance from SPINRAZA, along with contributions from new launches like SKYCLARYS and QALSODY. Alzheimer's collaboration revenue from LEQEMBI also saw a substantial increase, reflecting its ongoing market penetration. The company also announced a new corporate headquarters lease in Cambridge, MA, and continued to advance its pipeline through strategic collaborations and research funding.

Biogen Inc. has filed an 8-K report on May 1, 2025, to announce its financial results for the first quarter ended March 31, 2025. The primary purpose of this filing is to furnish a press release containing these operational and financial highlights. Investors should refer to the press release, attached as Exhibit 99.1, for detailed information regarding the company's performance during the quarter. While the 8-K itself is procedural, the accompanying press release will provide crucial insights into Biogen's revenue generation, profitability, and overall financial health for Q1 2025. Investors will be looking for updates on key product performance, pipeline developments, and any management commentary on future outlook and strategic initiatives. It is important to note that this information is furnished and not deemed 'filed' under Section 18 of the Exchange Act, meaning it does not carry the same legal implications for misstatements as a formally filed document.

Biogen Inc. (BIIB) has filed a Form 8-K on February 12, 2025, to report its financial results for the fourth quarter and full year ended December 31, 2024. The primary purpose of this filing is to provide investors with the company's performance data, which was announced via a press release furnished as Exhibit 99.1. Investors should refer to this press release for specific details on revenue, earnings, and other key financial metrics, as well as management's commentary on the results and outlook.

Biogen Inc.'s (BIIB) 10-K filing for the year ending December 31, 2024, highlights a company navigating a challenging market for its Multiple Sclerosis (MS) portfolio, which saw significant revenue decline primarily due to increased competition and a shift towards higher efficacy therapies. This decline was partially offset by growth in the Rare Disease segment, driven by new product launches like SKYCLARYS and QALSODY. The company made strategic moves, including the $1.15 billion acquisition of HI-Bio to bolster its immunology pipeline with felzartamab. Looking ahead, Biogen is focused on key pipeline advancements, including the ongoing development and regulatory submissions for LEQEMBI in Alzheimer's disease and pipeline expansion in neurology, specialized immunology, and rare diseases. The company is also implementing cost-reduction measures through its "Fit for Growth" program to improve efficiency. Investors should monitor Biogen's ability to successfully commercialize its newer assets, manage the decline in its established MS franchise, and navigate the competitive landscape, especially with the increasing impact of biosimilars and generic competition on products like TECFIDERA and TYSABRI.

Biogen Inc. has announced a key leadership transition in its finance department, effective March 1, 2025. Sean Godbout has been appointed as the new Vice President, Chief Accounting Officer & Global Corporate Controller, and will also serve as the Company's principal accounting officer. This appointment is part of a broader leadership evolution within the finance team, as Robin Kramer, the current Chief Accounting Officer, transitions to the role of Chief Financial Officer upon the retirement of Michael McDonnell on the same date. Mr. Godbout brings extensive experience to his new role, having been with Biogen since 2007 and most recently serving as Global Corporate Controller. His compensation package includes a base salary of $400,000, eligibility for an annual bonus plan, and long-term incentive grants. The filing also outlines the severance benefits Mr. Godbout is entitled to under the company's executive severance plan for Vice Presidents, which includes provisions for termination without cause and in connection with a corporate change of control. Investors should note this as a routine but important update regarding financial leadership continuity.

Biogen Inc. (BIIB) announced a planned leadership transition in its finance department via an 8-K filing dated October 30, 2024. Chief Financial Officer Michael McDonnell will retire effective February 28, 2025, after a distinguished tenure. To ensure a seamless handover, Mr. McDonnell will work closely with his successor, Robin Kramer, who has been appointed as the new Chief Financial Officer. Ms. Kramer's appointment will be effective upon Mr. McDonnell's retirement, signaling a new chapter for Biogen's financial leadership.

Biogen Inc. reported net income of $388.5 million, or $2.66 per diluted share, for the third quarter of 2024, a significant improvement from a net loss of $68.1 million in the same period last year. This turnaround was driven by a substantial decrease in total costs and expenses, including lower R&D and SG&A expenses, partly due to the phasing out of acquisition-related equity compensation costs recognized in the prior year. Total revenue saw a slight decrease of 2.5% to $2.47 billion, mainly impacted by a 9.1% decline in Multiple Sclerosis (MS) product revenue due to increased competition, particularly for TYSABRI and TECFIDERA. The company successfully completed the acquisition of HI-Bio for $1.15 billion in July 2024, adding felzartamab to its pipeline for severe immune-mediated diseases. This strategic move is expected to bolster Biogen's immunology and rare disease portfolios. While overall MS revenue continues to face challenges from generic competition and shifting patient preferences towards higher efficacy therapies, the Rare Disease segment showed strong growth, primarily driven by the initial sales of SKYCLARYS, acquired through the Reata transaction in late 2023. Biogen's financial position remains solid with cash and cash equivalents increasing to $1.7 billion. The company generated $2.1 billion in operating cash flow for the first nine months of the year. Despite ongoing competitive pressures in key therapeutic areas, Biogen's focus on pipeline advancement and strategic acquisitions positions it to navigate the evolving biopharmaceutical landscape. Investors should monitor the performance of newer products like SKYCLARYS and the progress of pipeline assets such as felzartamab, while also considering the continued challenges in the MS segment.

Biogen Inc. (BIIB) has filed a Form 8-K on October 30, 2024, to report its financial results for the third quarter ended September 30, 2024. The primary purpose of this filing is to furnish the press release announcing these results, which provides key operational and financial information to investors. While this filing itself doesn't contain detailed financial statements, it directs investors to the attached press release for the comprehensive quarterly update. Investors should focus on the press release (Exhibit 99.1) for specific details regarding revenue, earnings per share, operating expenses, and any forward-looking guidance. This report serves as the official notification of the release of Biogen's Q3 2024 performance data, allowing the market to assess the company's ongoing business trends and strategic execution.

Biogen Inc. announced an expansion of its Board of Directors with the appointment of two new independent directors, Dr. Lloyd Minor and Professor Sir Menelas Pangalos. Dr. Minor's appointment is effective October 1, 2024, while Professor Sir Pangalos will join on January 1, 2025. Both are expected to serve until the company's 2025 Annual Meeting of Stockholders. These appointments bring significant expertise to Biogen's board, with Dr. Minor being a prominent figure in academic medicine and university leadership, and Professor Sir Pangalos having extensive experience in neuroscience research and development within the pharmaceutical industry. Investors should view these additions as a positive step towards strengthening the board's strategic oversight and scientific acumen, potentially enhancing the company's innovation and long-term growth prospects.

Biogen Inc. (BIIB) announced on August 14, 2024, through an 8-K filing, the entry into a new $1.5 billion, five-year unsecured, revolving credit facility with Bank of America, N.A. This new facility replaces the Company's previous credit agreement. As of the closing date, no funds had been drawn under this new facility, indicating Biogen maintains a strong liquidity position. The new credit agreement provides Biogen with significant financial flexibility for general corporate purposes. The interest rates are variable, tied to benchmark rates like SOFR, EURIBOR, etc., plus an applicable margin that depends on the Company's debt ratings. The facility includes sub-limits for letters of credit and swing line loans. Importantly, the agreement includes a financial covenant requiring Biogen to maintain a consolidated leverage ratio of no more than 3.75 to 1.0, with a temporary increase allowed to 4.25 to 1.0 in case of material acquisitions.

Biogen Inc. reported a slight increase in total revenue for the three months ended June 30, 2024, reaching $2,464.9 million, a 0.4% rise year-over-year. This was primarily driven by a 2.9% increase in product revenue, largely from the rare disease segment, which saw a significant boost from SKYCLARYS sales. However, revenue from contract manufacturing, royalty, and other sources declined by 31.7%. Diluted earnings per share decreased by 1.7% to $4.00, reflecting higher amortization costs related to the Reata acquisition's intangible assets and a substantial increase in 'Other (income) expense, net,' which more than offset a decrease in R&D and cost of sales. The company also announced the completion of the HI-Bio acquisition for $1.15 billion, funded by existing cash, and the sale of a priority review voucher for $103.0 million, contributing to a substantial increase in cash and cash equivalents to $1.9 billion.

Biogen Inc. (BIIB) has filed an 8-K on August 1, 2024, to report its financial results for the second quarter ended June 30, 2024. The core of this filing is the press release, furnished as Exhibit 99.1, which details the company's operational performance and financial condition. Investors should refer to this press release for the specific quantitative and qualitative information regarding the quarter's results. While the 8-K itself is a formal filing, it directs stakeholders to the accompanying press release for the critical financial data. This is a standard procedure for earnings announcements, meaning the detailed performance metrics, revenue figures, profitability, and any forward-looking statements are contained within the furnished press release, which is incorporated by reference into this filing.

Biogen Inc. filed an 8-K on June 25, 2024, detailing the outcomes of its 2024 Annual Meeting of Stockholders held on June 20, 2024. The most significant event from an investor perspective was the approval of an amendment to the Company's Certificate of Incorporation to allow for the exculpation of certain company officers, to the extent permitted by Delaware law. This change, which was previously approved by the Board of Directors, aims to provide a layer of protection for officers against certain liabilities. Additionally, the filing provides the final voting results for all proposals presented at the meeting. These included the election of nine directors to the Board, the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2024, an advisory vote on executive compensation, and the approval of two equity incentive plans: the 2024 Omnibus Equity Plan and the 2024 Employee Stock Purchase Plan. All proposals received substantial support from stockholders, indicating general alignment with management's decisions and governance.

Biogen Inc. (BIIB) filed an 8-K on April 24, 2024, to report its financial results for the first quarter ended March 31, 2024. The core of this filing is the press release attached as Exhibit 99.1, which contains the company's operational and financial performance for the period. Investors should refer to this press release for detailed information regarding Biogen's Q1 2024 earnings, including revenue, profitability, and any forward-looking guidance provided. This 8-K serves as a notification of the release of these results and incorporates the press release by reference. While the 8-K itself is a formal SEC filing, the substantive financial details and commentary are contained within the accompanying press release. Investors and analysts will be reviewing these figures closely to assess the company's performance against expectations and to understand the strategic direction and outlook for Biogen in the coming quarters, particularly concerning its key therapeutic areas and product portfolio.

Biogen Inc. (BIIB) reported a decrease in total revenue for the first quarter of 2024, down 7.0% year-over-year to $2.29 billion. This decline was primarily driven by a significant drop in contract manufacturing, royalty, and other revenue, which fell 38.5% to $184.6 million. Product revenue also saw a modest decrease of 2.9% to $1.71 billion, largely due to ongoing generic competition impacting Multiple Sclerosis (MS) revenues, which decreased by 4.4%, and a decrease in Rare Disease revenue by 4.4%. Despite the revenue challenges, the company managed to increase its net income to $393.4 million, a slight rise from $387.9 million in the prior year's quarter, resulting in diluted earnings per share of $2.70, up from $2.67. The company also demonstrated strong operational cash flow generation of $553.2 million.

Biogen Inc.'s 2023 10-K filing highlights a year marked by significant strategic moves, including the substantial acquisition of Reata Pharmaceuticals for approximately $6.6 billion, which brought SKYCLARYS for Friedreich's Ataxia into their portfolio. This acquisition, alongside other product launches like QALSODY for ALS and ZURZUVAE for postpartum depression, signals a strategic pivot towards rare diseases and neurology, particularly in Alzheimer's disease with the traditional FDA approval and expanded coverage for LEQEMBI. However, the company faces considerable headwinds, most notably a significant decline in revenue from its Multiple Sclerosis (MS) franchise, driven by increased competition from generics and biosimilars, particularly impacting TECFIDERA. This decline is a major concern for investors, as the MS segment has historically been a core revenue driver. Despite these challenges, Biogen is implementing a "Fit for Growth" program aimed at achieving significant cost savings by 2025. The company's financial health remains robust, supported by a strong cash position, though reduced significantly by the Reata acquisition, and the absence of share repurchases in 2023.

Biogen Inc. announced its fourth quarter and full-year 2023 financial results on February 13, 2024, via a press release filed as an 8-K. While the filing itself primarily serves to incorporate the press release, the key information for investors lies within the reported financial performance and operational updates. Investors should review the furnished press release for detailed figures on revenue, profitability, and any forward-looking guidance provided by the company. The press release will offer insights into the company's performance drivers, such as sales of key products and any progress or setbacks in its drug pipeline, which are crucial for understanding Biogen's current financial health and future prospects.

Biogen Inc. (BIIB) filed an 8-K on December 12, 2023, detailing amendments to its Fifth Amended and Restated Bylaws, effective December 6, 2023. The primary focus of these amendments is to update procedural mechanics and disclosure requirements related to stockholder meetings, particularly concerning the submission of business proposals and director nominations. These changes aim to enhance transparency and streamline the proxy solicitation process. Key updates include more stringent disclosure requirements for stockholders proposing business, such as detailing derivative or synthetic arrangements that mirror long positions in company shares. Additionally, provisions related to director nominations have been enhanced to align with Rule 14a-19 of the Securities Exchange Act, requiring significant proxy solicitation efforts (at least 67% of voting power) and specific disclosures from nominating stockholders and their nominees. The amendments also clarify procedures for meeting adjournments, quorum establishment, and the revocability of proxies.

Biogen Inc. (BIIB) filed an 8-K on November 8, 2023, primarily to furnish its press release announcing third-quarter 2023 results. While the filing itself contains minimal new information beyond the announcement of the press release, investors should refer to the furnished press release (Exhibit 99.1) for detailed financial and operational performance updates. This filing serves as the official notification of the release of these results.

Biogen Inc. announced a key addition to its Board of Directors, effective January 1, 2024. Monish Patolawala has been elected as a new director, filling a vacancy and serving until the 2024 Annual Meeting. Mr. Patolawala's expertise is particularly noteworthy as he qualifies as an "audit committee financial expert," a designation important for oversight of financial reporting and internal controls. This appointment suggests a continued focus on robust financial governance and potentially strengthens the composition of the Board's Audit Committee, should he be appointed to it.

Biogen Inc. reported a net loss of $68.1 million for the third quarter of 2023, a significant change from the $1.13 billion net income in the same period last year. This shift was primarily driven by a substantial increase in total costs and expenses, particularly R&D and SG&A expenses, largely due to one-time costs associated with the acquisition of Reata Pharmaceuticals. Total revenue saw a slight increase of 0.9% to $2.53 billion, driven by growth in contract manufacturing and royalty revenue, which offset a 8.0% decline in product revenue. The decrease in product revenue was mainly attributed to ongoing generic competition for TECFIDERA and increased competition for TYSABRI, partially offset by growth in SPINRAZA. Operationally, the company completed the significant acquisition of Reata for approximately $7.2 billion, adding SKYCLARYS, a treatment for Friedreich's Ataxia, to its portfolio. This acquisition, while strategically important, significantly impacted the company's financial results for the quarter due to associated expenses. Management is also progressing with a 'Fit for Growth' program aimed at reducing operating costs by approximately $1.0 billion by 2025 through measures including headcount reductions. The company's cash position decreased significantly due to the Reata acquisition, but Biogen maintains adequate liquidity.

This amendment to Biogen Inc.'s (BIIB) 8-K filing provides an update on the outcome of an advisory vote concerning the "Say-on-Frequency" proposal presented at its Annual Meeting. The company's stockholders expressed a preference for the "Say-on-Pay" advisory vote to be conducted annually. Consequently, Biogen's Board of Directors has determined that future "Say-on-Pay" votes will indeed be held every year.

Biogen Inc. has announced the successful completion of its acquisition of Reata Pharmaceuticals, Inc. on September 26, 2023. This significant event marks a strategic move for Biogen, aiming to enhance its portfolio and future growth prospects through the integration of Reata's assets and pipeline. Investors should note that this acquisition is expected to impact Biogen's commercial business, R&D pipeline, and overall financial and operating results, as detailed in the company's forward-looking statements. The press release accompanying this filing contains extensive forward-looking statements regarding the potential benefits and expected outcomes of this transaction, as well as Biogen's broader strategic initiatives like the 'Fit for Growth' program. While the company expresses optimism about the future, it also acknowledges the inherent risks and uncertainties associated with drug development, commercialization, and the integration of acquired businesses. Investors are advised to review Biogen's SEC filings for a comprehensive understanding of these risks.

Biogen Inc. (BIIB) announced on September 1, 2023, its entry into a new $1.5 billion unsecured credit facility with JPMorgan Chase Bank, N.A., effective August 28, 2023. This facility is designed to fund a significant portion of the consideration for Biogen's previously announced acquisition of Reata Pharmaceuticals, Inc., as well as repay certain Reata indebtedness and related expenses. The credit facility is comprised of two tranches: a $750 million 364-day tranche (Tranche A) and a $750 million three-year tranche (Tranche B). The new credit facility replaces a previously announced bridge loan facility. The interest rates on borrowings will be tied to either Term SOFR or a Base Rate, plus an applicable margin based on Biogen's debt ratings. The agreement includes customary covenants and events of default, as well as a financial covenant requiring Biogen to maintain a maximum consolidated leverage ratio of 3.5 to 1.0, which can temporarily increase to 4.0 to 1.0 under specific circumstances related to the Reata acquisition and other material acquisitions.

Biogen Inc. (BIIB) has announced a material definitive agreement to acquire Reata Pharmaceuticals, Inc. through a merger. This strategic move involves Biogen acquiring all outstanding shares of Reata's common stock for a cash consideration of $172.50 per share, valuing the transaction at a significant amount. The merger agreement has been unanimously approved by the boards of directors of both companies, indicating strong support for the transaction. This acquisition is expected to be financed through a combination of Biogen's existing cash reserves and a new $1.5 billion bridge loan facility, demonstrating Biogen's financial capacity to complete the deal. The transaction is subject to customary closing conditions, including Reata stockholder approval and regulatory clearances. This acquisition represents a significant step in Biogen's growth strategy, likely aimed at expanding its therapeutic portfolio and market presence. Investors should monitor the progress of Reata's stockholder approval process and any regulatory reviews. The definitive agreement includes customary provisions such as representations, warranties, and covenants, along with 'no-shop' clauses to prevent Reata from soliciting competing offers, though exceptions exist for superior proposals. The 'Fit for Growth' program mentioned in the cautionary notes suggests ongoing efforts by Biogen to optimize its operations and financial structure alongside strategic acquisitions.

Biogen Inc. (BIIB) announced a significant strategic move through an 8-K filing on July 28, 2023, detailing its entry into a definitive agreement to acquire Reata Pharmaceuticals, Inc. (Reata). This transaction, structured as a merger where Reata will become a wholly-owned subsidiary of Biogen, represents a substantial investment aimed at bolstering Biogen's pipeline and commercial offerings. The announcement was accompanied by a joint press release and an investor webcast presentation, which are attached as exhibits to the filing. This acquisition signals Biogen's commitment to growth and expansion, likely focusing on Reata's therapeutic areas which may complement Biogen's existing portfolio. Investors should closely monitor the progress of this merger, including the satisfaction of closing conditions and regulatory approvals, as it could materially impact Biogen's future financial performance, strategic direction, and market position. The cautionary note included highlights the inherent risks and uncertainties associated with drug development, commercialization, and significant corporate transactions like this proposed merger.

Biogen Inc. reported a decrease in total revenue for the second quarter of 2023, primarily driven by a significant decline in Multiple Sclerosis (MS) product revenue due to increased generic competition for TECFIDERA and market shifts away from Interferon therapies. While Spinal Muscular Atrophy (SMA) revenue saw a slight increase, the overall product revenue was down 10.2% year-over-year. This revenue decline, coupled with an increase in cost of sales and R&D expenses, led to a substantial decrease in net income and diluted earnings per share compared to the prior year period. However, the company's cash position remains strong, with a significant increase in cash, cash equivalents, and marketable securities, bolstered by a substantial payment received from the Samsung Bioepis sale. The company also announced a new "Fit for Growth" program aimed at significant operating expense savings.